Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Official Title

A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Summary:

To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies

Trial Description

Primary Outcome:

• Define the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of oral daily ENMD 2076 by evaluation of adverse events

• Safety and toxicity of repeated oral dosing of ENMD 2076
• Describe any preliminary evidence of anti-cancer effects of ENMD-2076 in patients with hematological malignancies

View this trial on ClinicalTrials.gov